Logo image of VTRS

VIATRIS INC (VTRS) Stock Price, Forecast & Analysis

USA - Nasdaq - NASDAQ:VTRS - US92556V1061 - Common Stock

12.45 USD
-0.09 (-0.72%)
Last: 12/31/2025, 8:00:02 PM
12.42 USD
-0.03 (-0.24%)
After Hours: 12/31/2025, 8:00:02 PM

VTRS Key Statistics, Chart & Performance

Key Statistics
Market Cap14.34B
Revenue(TTM)14.12B
Net Income(TTM)-3.69B
Shares1.15B
Float1.15B
52 Week High12.62
52 Week Low6.85
Yearly Dividend0.48
Dividend Yield3.92%
EPS(TTM)2.33
PE5.34
Fwd PE4.94
Earnings (Next)02-25 2026-02-25/amc
IPO1973-02-01
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals


VTRS short term performance overview.The bars show the price performance of VTRS in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 10 20 30

VTRS long term performance overview.The bars show the price performance of VTRS in the last 1, 2 and 3 years. 1 year 2 years 3 years 5 10

The current stock price of VTRS is 12.45 USD. In the past month the price increased by 16.25%. In the past year, price increased by 1.38%.

VIATRIS INC / VTRS Daily stock chart

VTRS Latest News, Press Relases and Analysis

VTRS Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 48.87 1.02T
JNJ JOHNSON & JOHNSON 19.94 498.60B
MRK MERCK & CO. INC. 11.95 261.26B
PFE PFIZER INC 7.78 141.57B
BMY BRISTOL-MYERS SQUIBB CO 8.22 109.81B
ZTS ZOETIS INC 19.85 55.45B
RPRX ROYALTY PHARMA PLC- CL A 9.4 22.30B
ELAN ELANCO ANIMAL HEALTH INC 23.57 11.24B
AXSM AXSOME THERAPEUTICS INC N/A 9.21B
BLTE BELITE BIO INC - ADR N/A 5.58B
CRNX CRINETICS PHARMACEUTICALS IN N/A 4.42B
GPCR STRUCTURE THERAPEUTICS INC N/A 4.22B

About VTRS

Company Profile

VTRS logo image Viatris, Inc. is a global healthcare company, which engages in the provision of healthcare and pharmaceutical products. The company is headquartered in Canonsburg, Pennsylvania and currently employs 32,000 full-time employees. The firm's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in China, Taiwan and Hong Kong. The JANZ segment reflects its operations in Japan, Australia, and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, including in Asia, Africa, Eastern Europe, Latin America, and the Middle East, as well as the Company’s Antiretroviral medicines (ARV) franchise. Its pipeline and research and development capabilities include expertise in formulation, device development, toxicology, analytical, clinical, bioanalytical, medical affairs, product safety and risk management across a range of therapeutic areas. The company produces oral solid doses, injectables, and products with complex dosage forms.

Company Info

VIATRIS INC

1000 Mylan Boulevard

Canonsburg PENNSYLVANIA 15317 US

CEO: Michael Goettler

Employees: 32000

VTRS Company Website

VTRS Investor Relations

Phone: 17245141465

VIATRIS INC / VTRS FAQ

What does VIATRIS INC do?

Viatris, Inc. is a global healthcare company, which engages in the provision of healthcare and pharmaceutical products. The company is headquartered in Canonsburg, Pennsylvania and currently employs 32,000 full-time employees. The firm's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in China, Taiwan and Hong Kong. The JANZ segment reflects its operations in Japan, Australia, and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, including in Asia, Africa, Eastern Europe, Latin America, and the Middle East, as well as the Company’s Antiretroviral medicines (ARV) franchise. Its pipeline and research and development capabilities include expertise in formulation, device development, toxicology, analytical, clinical, bioanalytical, medical affairs, product safety and risk management across a range of therapeutic areas. The company produces oral solid doses, injectables, and products with complex dosage forms.


What is the current price of VTRS stock?

The current stock price of VTRS is 12.45 USD. The price decreased by -0.72% in the last trading session.


Does VTRS stock pay dividends?

VIATRIS INC (VTRS) has a dividend yield of 3.92%. The yearly dividend amount is currently 0.48.


How is the ChartMill rating for VIATRIS INC?

VTRS has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 4 out of 10.


What do analysts say about VIATRIS INC (VTRS) stock?

17 analysts have analysed VTRS and the average price target is 12.71 USD. This implies a price increase of 2.05% is expected in the next year compared to the current price of 12.45.


Can you provide the sector and industry classification for VIATRIS INC?

VIATRIS INC (VTRS) operates in the Health Care sector and the Pharmaceuticals industry.


What is the market capitalization of VTRS stock?

VIATRIS INC (VTRS) has a market capitalization of 14.34B USD. This makes VTRS a Large Cap stock.


VTRS Technical Analysis

ChartMill assigns a technical rating of 8 / 10 to VTRS. When comparing the yearly performance of all stocks, VTRS is one of the better performing stocks in the market, outperforming 77.49% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

VTRS Fundamental Analysis

ChartMill assigns a fundamental rating of 4 / 10 to VTRS. There are concerns on the financial health of VTRS while its profitability can be described as average.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

VTRS Financial Highlights

Over the last trailing twelve months VTRS reported a non-GAAP Earnings per Share(EPS) of 2.33. The EPS decreased by -14.65% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -9.73%
ROE -24.26%
Debt/Equity 0.82
Chartmill High Growth Momentum
EPS Q2Q%-10.67%
Sales Q2Q%0.23%
EPS 1Y (TTM)-14.65%
Revenue 1Y (TTM)-6.14%

VTRS Forecast & Estimates

17 analysts have analysed VTRS and the average price target is 12.71 USD. This implies a price increase of 2.05% is expected in the next year compared to the current price of 12.45.

For the next year, analysts expect an EPS growth of -10.8% and a revenue growth -4.73% for VTRS


Analysts
Analysts71.76
Price Target12.71 (2.09%)
EPS Next Y-10.8%
Revenue Next Year-4.73%

VTRS Ownership

Ownership
Inst Owners86.85%
Ins Owners0.25%
Short Float %2.43%
Short Ratio3.24